DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 00D–1631]

International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); Draft Guidance for Industry on “Safety Studies for Veterinary Drug Residues in Human Food: Genotoxicity Studies” (VICH GL23); Availability; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability for comment of a draft guidance document for industry (No. 116) entitled “Safety Studies for Veterinary Drug Residues in Human Food: Genotoxicity Studies” (VICH GL23). This draft guidance document has been adapted for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) from a guidance regarding pharmaceuticals for human use, which was adopted by the International Conference on Harmonisation of Technical Requirements for Approval of Pharmaceuticals for Human Use (ICH). This draft VICH guidance document recommends a basic battery of tests that can be used to evaluate the genotoxicity of veterinary drug residues in human food in the European Union, Japan, and the United States.

DATES: Submit written comments on the draft guidance document by [insert date 30 days after date of publication in the Federal Register], to ensure their adequate consideration in preparation of the final guidance document. General comments on agency guidance documents are welcome at any time.
ADDRESSES: Copies of the draft guidance document entitled “Safety Studies for Veterinary Drug Residues in Human Food: Genotoxicity Studies” (VICH GL23) may be obtained on the Internet from the CVM home page at http://www.fda.gov/cvm/fda/TOCs/guideline.html. Persons without Internet access may submit written requests for single copies of the draft guidance document to the Communications Staff (HFV–12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests.

You may submit written comments on the draft guidance document to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Regarding the VICH: Sharon Thompson, Center for Veterinary Medicine, (HFV–3), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1798, e-mail: sthompso@cvm.fda.gov, or Carole R. Andres, Center for Veterinary Medicine (HFV–1), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6524, e-mail: candres1@cvm.fda.gov.

Regarding the draft guidance document: Louis T. Mulligan, Center for Veterinary Medicine (HFV–153), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6984, e-mail: lmulliga@cvm.fda.gov.

SUPPLEMENTARY INFORMATION:

I. Background

In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote the international harmonization of regulatory requirements. FDA has participated in efforts to enhance harmonization and has expressed its commitment to seek scientifically based harmonized technical procedures for the development of pharmaceutical
products. One of the goals of harmonization is to identify and then reduce differences in technical requirements for drug development among regulatory agencies in different countries.

FDA has actively participated in the ICH for several years to develop harmonized technical requirements for the approval of human pharmaceutical and biological products among the European Union, Japan, and the United States. The VICH is a parallel initiative for veterinary medicinal products. The VICH is concerned with developing harmonized technical requirements for the approval of veterinary medicinal products in the European Union, Japan, and the United States, and includes input from both regulatory and industry representatives.

The VICH Steering Committee is composed of member representatives from the: European Commission; European Medicines Evaluation Agency; European Federation of Animal Health; Committee on Veterinary Medicinal Products; U.S. FDA; U.S. Department of Agriculture; Animal Health Institute; Japanese Veterinary Pharmaceutical Association; Japanese Association of Veterinary Biologics; and Japanese Ministry of Agriculture, Forestry, and Fisheries.

Two observers are eligible to participate in the VICH Steering Committee: One representative from the Government of Australia/New Zealand and one representative from the industry in Australia/New Zealand. The VICH Secretariat, which coordinates the preparation of documentation, is provided by the Confédération Mondiale de L’Industrie de la Santé Animale (COMISA). A COMISA representative also participates in the VICH Steering Committee meetings.

II. Draft Guidance on Genotoxicity Studies

The VICH Steering Committee held a meeting on June 14 through 16, 2000, and agreed that the draft guidance document entitled “Safety Studies for Veterinary Drug Residues in Human Food: Genotoxicity Studies” (VICH GL23) should be made available for public comment. This draft guidance document has been adapted for veterinary use by the VICH from guidances regarding pharmaceuticals for human use which were adopted by the ICH and published in the Federal Register of April 24, 1996 (61 FR 18197), and November 21, 1997 (62 FR 62471). This draft guidance document is one of a series of VICH guidances developed to facilitate the mutual
acceptance of safety data necessary for the establishment of acceptable daily intakes for veterinary
drug residues in human food by the relevant regulatory authorities. The guidance on the overall
strategy for the evaluation of veterinary drug residues in human food (VICH Guidance on General
Testing Approach) will be made available at a later time. This guidance was developed after
consideration of the existing ICH guidances for pharmaceuticals for human use: “Genotoxicity:
A Standard Battery of Genotoxicity Testing of Pharmaceuticals” and “Guidance on Specific Aspects
of Regulatory Genotoxicity Tests for Pharmaceuticals.” Account was also taken of the Organisation
for Economic Cooperation and Development methodological guidances and of the current practices
for evaluating the safety of veterinary drug residues in human food in the European Union, Japan,
the U.S.A., Australia, and New Zealand.

Comments about the draft guidance documents will be considered by the FDA and the VICH
Safety Working Group. Ultimately, FDA intends to adopt the VICH Steering Committee’s final
guidances and publish them as future guidance. (Information collection is covered under OMB
No. 0910–0117. Information collection also could be covered by OMB No. 0910–0032.)

III. Significance of Guidance

This draft guidance document, developed under the VICH process, has been revised to conform
to FDA’s good guidance practices regulation (65 FR 56468, September 19, 2000). For example,
the documents have been designated “guidance” rather than “guideline.” Because guidance
documents are not binding, unless specifically supported by statute or regulation, mandatory words
such as “must,” “shall,” and “will” in the original VICH documents have been substituted with
“should.” Similarly, words such as “require” or “requirement” have been replaced by
“recommendation” or “recommended” as appropriate to the context.

The draft guidance document represents the agency’s current thinking on genotoxicity safety
studies for veterinary drug residues in human food. This guidance document does not create or
confer any rights for or on any person and will not operate to bind FDA or the public. An alternative
method may be used as long as it satisfies the requirements of applicable statutes and regulations.
IV. Comments

This draft guidance document is being distributed for comment purposes only and is not intended for implementation at this time. Interested persons may submit to the Dockets Management Branch (address above) written comments regarding this draft guidance document. Submit written comments by [insert date 30 days after date of publication in the Federal Register], to ensure adequate consideration in preparation of the final guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the draft guidance document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: \[12/8/00\]
December 8, 2000.

Margaret A. Dotzel
Associate Commissioner for Policy
[FR Doc. 00–???? Filed ??–??–00; 8:45 am]

BILLING CODE: 3510–22–S